A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)

Trial overview


Prostate cancer

Study details

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.

Eligibility criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of metastatic prostate cancer.
  • Candidate for treatment with enzalutamide, abiraterone acetate, or darolutamide with documented current evidence of metastatic prostate cancer.
  • Surgically or medically castrated.
  • Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) or Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
  • For Patients Recruited Specifically to Tumour Pharmacodynamic Cohorts:
  • Patients must have at least 1 tumour suitable for paired biopsies

Exclusion Criteria:

  • Any previous treatment with a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, Lu-PSMA, platinum chemotherapy, docetaxel (for mHSPC patients).
  • Radiotherapy within 4 weeks of the first dose of study treatment.

Further information

Please click here for more information


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.